IP Library Granted Patent US 10,718,005
Granted Patent B2
US 10,718,005 · App. 16/177,676 · Granted Jul 21, 2020

Self-immolative probes for enzyme activity detection

Inventors: Irina Lebedeva (Bronx, NY); Wayne Forrest Patton (Dix Hills, NY); Maciej Szczepanik (Mount Sinai, NY); Yuejun Xiang (Hollis Hills, NY); Praveen Pande (Holbrook, NY)
Assignee: Enzo Life Sciences, Inc
C12Q1/26C07D311/08C07D491/052C07D491/20C07D493/10C09K11/06C12Q1/37C12Q1/44C12Q1/485C09K2211/1022C09K2211/1088G01N2333/902G01N2500/00Y10T436/18
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,718,005
App. No.
16/177,676
Granted
Jul 21, 2020
Kind
B2
Abstract

Provided is a compound having the structure: (SIG)-(SI-MOD) m where SIG is a signaling molecule, SI is a self-immolative structure bound to SIG such that SIG has a reduced signal relative to the signal of SIG without SI, MOD is a moiety bound to SI that is subject to modification by an activator, and m is an integer from 1 to about 10. When MOD is modified by an activator, SI is destabilized and self-cleaved from SIG such that SIG generates an increased signal. Also provided are methods of determining whether a sample, such as a cell, comprises an activator, such as a nitroreducase, using the compound. Further provided are methods of determining whether a mammalian cell is hypoxic using the compound where nitroreductase is the activator. A method of detecting a microorganism that comprises a nitroreductase using the compound where nitroreductase is the activator is also provided.

Claims (35)

1. A compound for detecting histone deacetylase activity, said compound consisting of the structure:

wherein SIG is a signaling moiety,

wherein SI is a self-immolative structure bound to SIG such that SIG has a reduced signal relative to the signal of SIG without SI,

wherein m is an integer from 1 to 10, and

wherein, when the compound is modified by histone deacetylase activity, SI is destabilized and self-cleaved from SIG such that SIG generates an increased signal.

2. The compound of claim 1 , wherein SIG is a fluorescent moiety or a luminescent moiety.

3. The compound of claim 1 , wherein m is an integer from 2 to 10.

4. The compound of claim 3 , wherein SIG is a fluorophore selected from a symmetric or asymmetric cyanine, a merocyanine, a styryl moiety, an oxazine, a xanthene, a coumarin, an iminocoumarin, a xanthene, a rhodamine, a rhodamine derivative, a rosamine, a rosamine derivative, a rhodol or a rhodol derivative.

5. The compound of claim 1 , wherein m=1.

6. The compound of claim 5 , wherein SIG is a fluorophore selected from a symmetric or asymmetric cyanine, a merocyanine, a styryl moiety, an oxazine, a xanthene, a coumarin, an iminocoumarin, a xanthene, a rhodamine, a rhodamine derivative, a rosamine, a rosamine derivative, a rhodol or a rhodol derivative.

7. The compound of claim 1 , consisting of the structure:

wherein each R 1 is independently a hydrogen, a halogen, Z, a cyano group, an isocyano group, a thiocyano group, an isothiocyano group, an azido group, a trihalomethyl group; a sulfonate group, a sulfate group, a carboxyl group, a carbonyl group, an ester group, an amido group, a carbamate group, a phosphate group, a phosphonate group, an amino group, an alkoxy group, a thiol group, a sulfoxy group, a sulfone group, a sulfonamide group, a phosphino group, or a silane group,

wherein Z is a reducible nitrogen-containing group, or an amino group bound to an electron deficient moiety, and

wherein n is 0, 1, 2, 3, or 4.

8. The compound of claim 7 , wherein SIG is a fluorescent moiety or a luminescent moiety.

9. The compound of claim 7 , wherein m is an integer from 2 to 10.

10. The compound of claim 9 , wherein SIG is a fluorophore selected from a symmetric or asymmetric cyanine, a merocyanine, a styryl moiety, an oxazine, a xanthene, a coumarin, an iminocoumarin, a xanthene, a rhodamine, a rhodamine derivative, a rosamine, a rosamine derivative, a rhodol or a rhodol derivative.

11. The compound of claim 7 , wherein m=1.

12. The compound of claim 11 , wherein SIG is a fluorophore selected from a symmetric or asymmetric cyanine, a merocyanine, a styryl moiety, an oxazine, a xanthene, a coumarin, an iminocoumarin, a xanthene, a rhodamine, a rhodamine derivative, a rosamine, a rosamine derivative, a rhodol or a rhodol derivative.

13. A method for detecting histone deacetylase activity in a sample, the method comprising

(a) incubating the sample with the compound of claim 1 for a time and under conditions sufficient for the compound to be modified by a histone deacetylase if present in the sample; and

(b) measuring the signal generated by SIG, wherein the amount of signal generated is proportional to the amount of histone deacetylase activity in the sample.

14. The method of claim 13 , wherein the sample is a fluid of an organism or a colony of organisms, or an extract thereof.

15. A method for detecting histone deacetylase activity in a sample, the method comprising

(a) incubating the sample with the compound of claim 7 for a time and under conditions sufficient for the compound to be modified by a histone deacetylase if present in the sample; and

(b) measuring the signal generated by SIG, wherein the amount of signal generated is proportional to the amount of histone deacetylase activity in the sample.

16. The method of claim 15 , wherein the sample is a fluid of an organism or a colony of organisms, or an extract thereof.

17. A compound consisting of the structure:

18. The compound of claim 17 , consisting of the structure:

19. The compound of claim 17 , consisting of the structure:

20. The compound of claim 17 , consisting of the structure:

21. A method for detecting histone deacetylase activity in a sample, the method comprising

(a) incubating the sample with the compound of claim 17 for a time and under conditions sufficient for the compound to be modified by a histone deacetylase if present in the sample; and

(b) measuring the luminescent signal generated by the compound, wherein the amount of signal generated is proportional to the amount of histone deacetylase activity in the sample.

22. The method of claim 21 , wherein the sample is a fluid of an organism or a colony of organisms, or an extract thereof.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Jul 24, 2023
From: GEMINO HEALTHCARE FINANCE, LLC D/B/A SLR HEALTHCARE ABL
To: ENZO BIOCHEM, INC.; ENZO CLINICAL LABS, INC.; ENZO LIFE SCIENCES U.S. HOLDING CORP; ENZO LIFE SCIENCES, INC.
Reel/Frame 064369/0031 →
SECURITY INTEREST Recorded Apr 3, 2023
From: ENZO LIFE SCIENCES, INC.; ENZO CLINICAL LABS, INC.; ENZO BIOCHEM, INC.; ENZO LIFE SCIENCES U.S. HOLDING CORP
To: GEMINO HEALTHCARE FINANCE, LLC D/B/A SLR HEALTHCARE ABL
Reel/Frame 063239/0103 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 27, 2018
From: SZCZEPANIK, MACIEJ; LEBEDEVA, IRINA V.; XIANG, YUEJUN; PANDE, PRAVEEN; PATTON, WAYNE FORREST
To: ENZO LIFE SCIENCES, INC.
Reel/Frame 047589/0597 →
Continuity (4)
Division 15416119 · Jan 26, 2017
Continuation 14447817 · Jul 31, 2014
Division 12927497 · Nov 16, 2010
Related Publication 20190119719A1 · Apr 25, 2019